EGFR and non-small cell lung carcinoma: A patient with EGFR mutation and EML4-ALK rearrangement, post-EGFR-TKI resistance, showed promising responses to combined EGFR and ALK inhibitors, suggesting a viable therapeutic approach for managing NSCLC with concurrent mutations.